Complement Membrane Attack Complex
"Complement Membrane Attack Complex" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC.
| Descriptor ID |
D015938
|
| MeSH Number(s) |
D12.776.124.486.274.930
|
| Concept/Terms |
Complement Membrane Attack Complex- Complement Membrane Attack Complex
- C5b-8-poly-C9
- C5b 8 poly C9
- Terminal Complement Complex
- Complement Complex, Terminal
- Complex, Terminal Complement
- Complement Complex C5b-9
- Complement Complex C5b 9
- Cytolytic Terminal Complement Complex
- Membrane Attack Complex
- C 5b-9
- C5b-9
|
Below are MeSH descriptors whose meaning is more general than "Complement Membrane Attack Complex".
Below are MeSH descriptors whose meaning is more specific than "Complement Membrane Attack Complex".
This graph shows the total number of publications written about "Complement Membrane Attack Complex" by people in this website by year, and whether "Complement Membrane Attack Complex" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 4 | 5 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Complement Membrane Attack Complex" by people in Profiles.
-
Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022 01 01; 57(1):95-105.
-
Complement levels at admission as a reflection of coronavirus disease 2019 (COVID-19) severity state. J Med Virol. 2021 09; 93(9):5515-5522.
-
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol. 2020; 11:599417.
-
Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020 12 08; 4(23):6051-6063.
-
Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest. 2020 11 02; 130(11):5967-5975.
-
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest. 2020 11 02; 130(11):6151-6157.
-
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020 10 29; 136(18):2080-2089.
-
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19. Clin Immunol. 2020 10; 219:108555.
-
Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics. Front Immunol. 2020; 11:1450.
-
Complement activation in patients with COVID-19: A novel therapeutic target. J Allergy Clin Immunol. 2020 Jul; 146(1):215-217.